Eagle Pharmaceuticals (EGRX) Competitors $3.00 0.00 (0.00%) As of 10/7/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EGRX vs. SAVA, ONCY, PYXS, CRDF, GLSI, CLYM, IVVD, ZYBT, CGEN, and HURAShould you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include Cassava Sciences (SAVA), Oncolytics Biotech (ONCY), Pyxis Oncology (PYXS), Cardiff Oncology (CRDF), Greenwich LifeSciences (GLSI), Climb Bio (CLYM), Invivyd (IVVD), Zhengye Biotechnology (ZYBT), Compugen (CGEN), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry. Eagle Pharmaceuticals vs. Its Competitors Cassava Sciences Oncolytics Biotech Pyxis Oncology Cardiff Oncology Greenwich LifeSciences Climb Bio Invivyd Zhengye Biotechnology Compugen TuHURA Biosciences Cassava Sciences (NASDAQ:SAVA) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Which has more risk & volatility, SAVA or EGRX? Cassava Sciences has a beta of -0.98, indicating that its stock price is 198% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Which has higher earnings and valuation, SAVA or EGRX? Eagle Pharmaceuticals has higher revenue and earnings than Cassava Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$24.34M-$2.55-1.56Eagle Pharmaceuticals$257.55M0.15$35.64MN/AN/A Do insiders and institutionals hold more shares of SAVA or EGRX? 38.1% of Cassava Sciences shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 2.4% of Cassava Sciences shares are held by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is SAVA or EGRX more profitable? Eagle Pharmaceuticals' return on equity of 0.00% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -66.16% -53.11% Eagle Pharmaceuticals N/A N/A N/A Do analysts rate SAVA or EGRX? Cassava Sciences presently has a consensus target price of $2.00, indicating a potential downside of 49.75%. Given Cassava Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Cassava Sciences is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer SAVA or EGRX? In the previous week, Cassava Sciences had 5 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 6 mentions for Cassava Sciences and 1 mentions for Eagle Pharmaceuticals. Cassava Sciences' average media sentiment score of 0.96 beat Eagle Pharmaceuticals' score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eagle Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryEagle Pharmaceuticals beats Cassava Sciences on 7 of the 11 factors compared between the two stocks. Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EGRX vs. The Competition Export to ExcelMetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.96M$1.05B$6.11B$10.56BDividend YieldN/A4.84%5.69%4.75%P/E RatioN/A1.2685.4827.60Price / Sales0.1528.98624.19239.62Price / Cash0.4017.6437.9261.55Price / BookN/A7.5213.136.76Net Income$35.64M-$7.77M$3.30B$275.88M7 Day Performance11.11%26.38%5.29%3.72%1 Month Performance-6.54%31.98%9.94%10.22%1 Year Performance445.45%66.40%87.78%35.86% Eagle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EGRXEagle Pharmaceuticals1.4274 of 5 stars$3.00flatN/A+361.5%$38.96M$257.55M0.00100SAVACassava Sciences3.0369 of 5 stars$2.90-7.8%$2.00-30.9%-86.5%$139.86MN/A-1.1430News CoverageAnalyst ForecastONCYOncolytics Biotech1.5336 of 5 stars$1.40-1.1%$5.00+258.4%-3.6%$139.50MN/A-5.1530Analyst ForecastPYXSPyxis Oncology1.9411 of 5 stars$2.18-1.1%$7.75+256.3%-25.0%$134.89M$2.82M-1.3660Positive NewsAnalyst ForecastCRDFCardiff Oncology2.5951 of 5 stars$2.03-2.6%$10.63+424.7%-16.1%$134.72M$680K-2.3320News CoveragePositive NewsAnalyst ForecastGLSIGreenwich LifeSciences1.1329 of 5 stars$9.87-2.9%$42.00+325.5%-17.5%$134.53MN/A-7.263CLYMClimb Bio4.0827 of 5 stars$1.98-0.5%$9.25+367.2%N/A$134.17MN/A-2.839Analyst UpgradeShort Interest ↓IVVDInvivyd3.6667 of 5 stars$1.09-3.1%$3.18+193.4%+76.9%$130.36M$46.21M-1.18100News CoverageAnalyst ForecastZYBTZhengye BiotechnologyN/A$2.74+25.1%N/AN/A$129.24M$186.36M0.00278High Trading VolumeCGENCompugen1.5854 of 5 stars$1.44-0.3%$4.00+178.7%-0.6%$128.06M$27.86M-6.5270News CoveragePositive NewsAnalyst ForecastGap DownHURATuHURA Biosciences1.7514 of 5 stars$2.47flat$12.67+412.8%N/A$123.87MN/A0.00N/APositive NewsAnalyst Forecast Related Companies and Tools Related Companies SAVA Alternatives ONCY Alternatives PYXS Alternatives CRDF Alternatives GLSI Alternatives CLYM Alternatives IVVD Alternatives ZYBT Alternatives CGEN Alternatives HURA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EGRX) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredHow to profit from the AI maniaPorter Stansberry says the AI boom’s next trillion-dollar winners won’t be chatbots or Big Tech — but the over...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
